Akari Therapeutics, Plc (AKTX)

NASDAQ: AKTX · Real-Time Price · USD

1.320

+0.060 (4.76%)

At close: May 12, 2025, 4:00 PM

1.385

+0.065 (4.92%)

After-hours: May 12, 2025, 4:05 PM EDT

Akari Therapeutics, Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Selling, General & Admin	9.66	11.36	13.53	8.08	9.16	Upgrade
Research & Development	6.98	5.45	9.56	9.13	8.82	Upgrade
Operating Expenses	16.65	16.81	23.09	17.21	17.98	Upgrade
Operating Income	-16.65	-16.81	-23.09	-17.21	-17.98	Upgrade
Interest Expense	-0.24	-	-	-	-	Upgrade
Interest & Investment Income	0.01	0.08	0.05	0.01	0.01	Upgrade
Currency Exchange Gain (Loss)	0.01	0.14	0.45	-0.19	0.35	Upgrade
Other Non Operating Income (Expenses)	2.08	6.58	4.84	-0.03	0.53	Upgrade
EBT Excluding Unusual Items	-14.8	-10.01	-17.75	-17.42	-17.08	Upgrade
Merger & Restructuring Charges	-5	-	-	-	-	Upgrade
Pretax Income	-19.79	-10.01	-17.75	-17.42	-17.08	Upgrade
Net Income	-19.79	-10.01	-17.75	-17.42	-17.08	Upgrade
Net Income to Common	-19.79	-10.01	-17.75	-17.42	-17.08	Upgrade
Shares Outstanding (Basic)	12	5	3	2	2	Upgrade
Shares Outstanding (Diluted)	12	5	3	2	2	Upgrade
Shares Change (YoY)	144.03%	56.79%	45.46%	35.87%	72.53%	Upgrade
EPS (Basic)	-1.66	-2.04	-5.69	-8.12	-10.81	Upgrade
EPS (Diluted)	-1.66	-2.04	-5.69	-8.12	-20.00	Upgrade
Free Cash Flow	-12.55	-16.43	-21.5	-18.85	-16.95	Upgrade
Free Cash Flow Per Share	-1.05	-3.36	-6.89	-8.78	-10.73	Upgrade
EBITDA	-16.63	-16.8	-23.08	-17.21	-17.97	Upgrade
D&A For EBITDA	0.01	0	0	0	0.01	Upgrade
EBIT	-16.65	-16.81	-23.09	-17.21	-17.98	Upgrade

Updated Nov 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q